Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 5/20 | 0.42 |
| ▸ | RARB | P10826 | 5/20 | 0.42 |
| ▸ | RARG | P13631 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 11/20 | 0.42 |
| ▸ | HNF4A | P41235 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033228 | 0.89 | RXRA (0.43) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6032628 | 0.89 | RXRA (0.43) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6562225 | 0.89 | RXRA (0.49) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6032585 | 0.87 | RXRA (0.44) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6032681 | 0.87 | L3MBTL1 (0.43) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6033270 | 0.87 | RARA (0.43) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6032651 | 0.84 | RXRA (0.41) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6032933 | 0.83 | RARG (0.49) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6032979 | 0.82 | RARA (0.48) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL6032928 | 0.81 | RARA (0.41) | RARARARBRARGRXRAHNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | claimed |
| US-6992094-B1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | TYR, DERL1, GPX1 | RARA 2083/4885RARB 2125/4885RARG 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.